Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Tofacitinib Citrate Tablets

Effects and efficacy:
Tofacitinib is suitable for adult patients with moderate to severe active rheumatoid arthritis (RA) who are inadequately treated with methotrexate or cannot tolerate it.

Dosage and administration:
The main use of tofacitinib is oral administration. It must be evaluated by a doctor before use and taken according to the doctor’s instructions. For adults without other conditions, the recommended dose is 5 mg twice a day, which can be taken with or without food. For patients receiving strong CYP3A4 inhibitors (such as ketoconazole), or a moderate CYP3A4 inhibitor and a strong CYP2C19 inhibitor (such as fluconazole), generally 5 mg once a day. For patients with moderate or severe renal impairment and moderate liver impairment, generally 5 mg once a day. This product can be used in combination with methotrexate or other non-biological DMARD drugs. For moderate or severe renal insufficiency or moderate liver impairment, the recommended dose of tofacitinib should be 5 mg once a day. For patients undergoing hemodialysis, it should be administered after dialysis on the dialysis day. If the drug is administered before the dialysis procedure, it is not recommended to supplement the drug after the patient’s dialysis. Patients with an absolute neutrophil count (ANC) between 500 and 1000 cells/mm should discontinue the drug as directed by the doctor and resume the drug when the ANC returns to above 1000, 5 mg twice a day. Patients with hemoglobin levels below 8g/dL or a decrease of more than 2g/dL should discontinue the drug as directed by the doctor until the hemoglobin value returns to normal.

Drug contraindications:
Contraindicated if allergic to this product
Related dosage forms: